Non-medical  switch  from  originator  to  biosimilar in fliximab  in  patients  with  inflammatory  arthritis: impact on s-infliximab and antidrug antibodies. Results from the Danish Rheumatological Biobank and the DANBIO registry

B Glintborg; T Kringelbach; E Høgdall; I J Sørensen; D V Jensen; A G Loft; O Hendricks; I M J Hansen; N Bolstad; D J Warren; J Gehin; G Goll; K L Grøn; G Eng; C Enevold; C H Nielsen; J S Johansen; M L Hetland

doi:10.1080/03009742.2016.1207299

Non-medical switch from originator to biosimilar in fliximab in patients with inflammatory arthritis: impact on s-infliximab and antidrug antibodies. Results from the Danish Rheumatological Biobank and the DANBIO registry

B Glintborg, T Kringelbach, E Høgdall, I J Sørensen, D V Jensen, A G Loft, O Hendricks, I M J Hansen, N Bolstad, D J Warren, J Gehin, G Goll, K L Grøn, G Eng, C Enevold, C H Nielsen, J S Johansen, M L Hetland

Institut for Klinisk Medicin

Originalsprog	Engelsk
Artikelnummer	OP10
Tidsskrift	Scandinavian Journal of Rheumatology
Vol/bind	45
Udgave nummer	sup128
Antal sider	2
ISSN	0300-9742
DOI	https://doi.org/10.1080/03009742.2016.1207299
Status	Udgivet - 2016

Adgang til dokumentet

10.1080/03009742.2016.1207299

Citationsformater

Glintborg, B., Kringelbach, T., Høgdall, E., Sørensen, I. J., Jensen, D. V., Loft, A. G., Hendricks, O., Hansen, I. M. J., Bolstad, N., Warren, D. J., Gehin, J., Goll, G., Grøn, K. L., Eng, G., Enevold, C., Nielsen, C. H., Johansen, J. S., & Hetland, M. L. (2016). Non-medical switch from originator to biosimilar in fliximab in patients with inflammatory arthritis: impact on s-infliximab and antidrug antibodies. Results from the Danish Rheumatological Biobank and the DANBIO registry. Scandinavian Journal of Rheumatology, 45(sup128), [OP10]. https://doi.org/10.1080/03009742.2016.1207299

Non-medical switch from originator to biosimilar in fliximab in patients with inflammatory arthritis : impact on s-infliximab and antidrug antibodies. Results from the Danish Rheumatological Biobank and the DANBIO registry. / Glintborg, B; Kringelbach, T; Høgdall, E et al.

I: Scandinavian Journal of Rheumatology, Bind 45, Nr. sup128, OP10, 2016.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Glintborg, B, Kringelbach, T, Høgdall, E, Sørensen, IJ, Jensen, DV, Loft, AG, Hendricks, O, Hansen, IMJ, Bolstad, N, Warren, DJ, Gehin, J, Goll, G, Grøn, KL, Eng, G, Enevold, C, Nielsen, CH, Johansen, JS & Hetland, ML 2016, 'Non-medical switch from originator to biosimilar in fliximab in patients with inflammatory arthritis: impact on s-infliximab and antidrug antibodies. Results from the Danish Rheumatological Biobank and the DANBIO registry', Scandinavian Journal of Rheumatology, bind 45, nr. sup128, OP10. https://doi.org/10.1080/03009742.2016.1207299

Glintborg B, Kringelbach T, Høgdall E, Sørensen IJ, Jensen DV, Loft AG et al. Non-medical switch from originator to biosimilar in fliximab in patients with inflammatory arthritis: impact on s-infliximab and antidrug antibodies. Results from the Danish Rheumatological Biobank and the DANBIO registry. Scandinavian Journal of Rheumatology. 2016;45(sup128):OP10. doi: 10.1080/03009742.2016.1207299

@article{009d7543b5b84991a3c9d0680179cd00,

title = "Non-medical switch from originator to biosimilar in fliximab in patients with inflammatory arthritis: impact on s-infliximab and antidrug antibodies. Results from the Danish Rheumatological Biobank and the DANBIO registry",

author = "B Glintborg and T Kringelbach and E H{\o}gdall and S{\o}rensen, {I J} and Jensen, {D V} and Loft, {A G} and O Hendricks and Hansen, {I M J} and N Bolstad and Warren, {D J} and J Gehin and G Goll and Gr{\o}n, {K L} and G Eng and C Enevold and Nielsen, {C H} and Johansen, {J S} and Hetland, {M L}",

year = "2016",

doi = "10.1080/03009742.2016.1207299",

language = "English",

volume = "45",

journal = "Scandinavian Journal of Rheumatology",

issn = "0300-9742",

publisher = "Taylor & Francis",

number = "sup128",

}

TY - ABST

T1 - Non-medical switch from originator to biosimilar in fliximab in patients with inflammatory arthritis

T2 - impact on s-infliximab and antidrug antibodies. Results from the Danish Rheumatological Biobank and the DANBIO registry

AU - Glintborg, B

AU - Kringelbach, T

AU - Høgdall, E

AU - Sørensen, I J

AU - Jensen, D V

AU - Loft, A G

AU - Hendricks, O

AU - Hansen, I M J

AU - Bolstad, N

AU - Warren, D J

AU - Gehin, J

AU - Goll, G

AU - Grøn, K L

AU - Eng, G

AU - Enevold, C

AU - Nielsen, C H

AU - Johansen, J S

AU - Hetland, M L

PY - 2016

Y1 - 2016

U2 - 10.1080/03009742.2016.1207299

DO - 10.1080/03009742.2016.1207299

M3 - Conference abstract in journal

SN - 0300-9742

VL - 45

JO - Scandinavian Journal of Rheumatology

JF - Scandinavian Journal of Rheumatology

IS - sup128

M1 - OP10

ER -